Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)

Market Cap	61.10M -11.8%
Revenue (ttm)	32.78M -21.0%
Net Income	-28.48M
EPS	-0.98
Shares Out	30.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,540
Open	2.000
Previous Close	2.010
Day's Range	2.000 - 2.010
52-Week Range	0.760 - 7.880
Beta	1.23
Analysts	n/a
Price Target	8.00 (+298.01%)
Earnings Date	Jul 8, 2026

About STO:NEWBRY

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NEWBRY

Financial Performance

In fiscal year 2025, STO:NEWBRY's revenue was 31.57 million, a decrease of -14.27% compared to the previous year's 36.83 million. Losses were -23.88 million, 55.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error